Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05294978
Recruiting Observational

EyeConic: Qualification for Cone-Optogenetics

NCT05294978 · tracked via the Priya Life Science Italy tracker
Sponsor
Institute of Molecular and Clinical Ophthalmology Basel
Phase
Observational
Started
2021-07-01
Last updated
2025-07-31

Condition(s) studied

Retinal Dystrophies

Investigational drug(s) / intervention(s)

Optical coherence tomography (OCT)

Optical coherence tomography (OCT): Data of macular optical coherence tomography (OCT)

Study summary

This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria (patients): * Diagnosis of generalized IRD * Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye * Availability of macular optical coherence tomography (OCT) Inclusion Criteria (controls): * Normal ophthalmic findings * Availability of macular optical coherence tomography (OCT) Exclusion Criteria (all): * Other eye diseases with a significant effect on vision or retinal structure * Extraocular disease affecting retinal structure such as neurodegenerative diseases

Primary outcome measure(s)

  • OCT - Central retinal volume — Baseline (about 10 minutes)
    Number of participants with preserved central retinal volume

Trial sites (9)

FacilityCityRegionStatus
University of California San Francisco, Department of Ophthalmology San Francisco California Recruiting
Bascom Palmer Eye Institute Miami Florida Recruiting
University of Pittsburgh, Department of Ophthalmology Pittsburgh Pennsylvania Recruiting
Beijing Institute of Ophthalmology Beijing China Recruiting
Universitätsklinikum Tübingen Augenklinik Tübingen Germany Recruiting
Semmelweis University, Department of Ophthalmology Budapest Hungary Recruiting
Oculista Ospedale Parma Parma Italy Recruiting
University Hospital Basel, Eye Clinic Basel Switzerland Recruiting
Moorfields Eye Hospital London United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05294978 on ClinicalTrials.gov ↗ ← All trials in Italy